JP2012528110A5 - - Google Patents

Download PDF

Info

Publication number
JP2012528110A5
JP2012528110A5 JP2012512352A JP2012512352A JP2012528110A5 JP 2012528110 A5 JP2012528110 A5 JP 2012528110A5 JP 2012512352 A JP2012512352 A JP 2012512352A JP 2012512352 A JP2012512352 A JP 2012512352A JP 2012528110 A5 JP2012528110 A5 JP 2012528110A5
Authority
JP
Japan
Prior art keywords
seq
binding protein
sequence number
antigen
asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012512352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012528110A (ja
JP5919188B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/057228 external-priority patent/WO2010136481A1/en
Publication of JP2012528110A publication Critical patent/JP2012528110A/ja
Publication of JP2012528110A5 publication Critical patent/JP2012528110A5/ja
Application granted granted Critical
Publication of JP5919188B2 publication Critical patent/JP5919188B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012512352A 2009-05-28 2010-05-26 Il−13結合タンパク質 Expired - Fee Related JP5919188B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18183309P 2009-05-28 2009-05-28
US61/181,833 2009-05-28
US28893009P 2009-12-22 2009-12-22
US61/288,930 2009-12-22
PCT/EP2010/057228 WO2010136481A1 (en) 2009-05-28 2010-05-26 Il-13 binding protein

Publications (3)

Publication Number Publication Date
JP2012528110A JP2012528110A (ja) 2012-11-12
JP2012528110A5 true JP2012528110A5 (https=) 2013-07-11
JP5919188B2 JP5919188B2 (ja) 2016-05-18

Family

ID=42335086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012512352A Expired - Fee Related JP5919188B2 (ja) 2009-05-28 2010-05-26 Il−13結合タンパク質

Country Status (21)

Country Link
US (2) US8680245B2 (https=)
EP (1) EP2435481A1 (https=)
JP (1) JP5919188B2 (https=)
KR (1) KR20120034679A (https=)
CN (1) CN102459341A (https=)
AR (1) AR078047A1 (https=)
AU (1) AU2010251955A1 (https=)
BR (1) BRPI1016061A2 (https=)
CA (1) CA2763443A1 (https=)
CO (1) CO6400150A2 (https=)
CR (1) CR20110664A (https=)
DO (1) DOP2011000347A (https=)
EA (1) EA201190275A1 (https=)
IL (1) IL216261A0 (https=)
MA (1) MA33381B1 (https=)
MX (1) MX2011012622A (https=)
PE (1) PE20120401A1 (https=)
SG (1) SG176203A1 (https=)
TW (1) TW201107345A (https=)
UY (1) UY32664A (https=)
WO (1) WO2010136481A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
BRPI1016061A2 (pt) 2009-05-28 2016-09-13 Glaxo Group Ltd "proteína de ligação de antígeno, célula hospedeira transfectada ou transformada recombinante, composição farmacêutica, método de tratamento de um paciente humano, uso de uma proteína de ligação de antígeno, método para a redução da agregação de um domínio variável simples de imunoglobulina, vk dab humano derivado de uma estrutura da linha germinativa, e, domínio variável simples de imunoglobulina."
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
CN113156138A (zh) * 2013-01-03 2021-07-23 梅索磅秤技术有限公司 测定实验对象组
JP2016522168A (ja) * 2013-04-05 2016-07-28 ジェネンテック, インコーポレイテッド 抗il−4抗体及び二重特異性抗体及びその使用
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
US9840553B2 (en) * 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016054114A1 (en) * 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
PE20180484A1 (es) * 2015-10-02 2018-03-07 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗il−13抗体を使用する、il−13活性が有害である疾患の治療方法
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
CN118005784A (zh) * 2022-11-08 2024-05-10 上海洛启生物医药技术有限公司 抗il-13长效纳米抗体序列及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
AU2003243189B2 (en) 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0414799D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Immunoglobulins
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
EP2441838A3 (en) * 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
BRPI0906261A2 (pt) 2008-03-31 2015-07-07 Genentech Inc "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
BRPI1016061A2 (pt) 2009-05-28 2016-09-13 Glaxo Group Ltd "proteína de ligação de antígeno, célula hospedeira transfectada ou transformada recombinante, composição farmacêutica, método de tratamento de um paciente humano, uso de uma proteína de ligação de antígeno, método para a redução da agregação de um domínio variável simples de imunoglobulina, vk dab humano derivado de uma estrutura da linha germinativa, e, domínio variável simples de imunoglobulina."

Similar Documents

Publication Publication Date Title
JP2012528110A5 (https=)
JP2022079549A5 (https=)
JP2015524790A5 (https=)
JP2018521638A5 (https=)
JP2020500538A5 (https=)
JP2013519364A5 (https=)
JP2009523154A5 (https=)
JP2012525829A5 (https=)
DK2406283T3 (en) ANTIBODY MOLECULES THAT HAVE BINDING SPECIFICITY TO HUMANT IL-13.
JP2021501744A5 (https=)
JP2011517447A5 (https=)
JP2020517249A5 (https=)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2011528902A5 (https=)
JP2010534478A5 (https=)
JP2015508762A5 (https=)
JP2012010714A5 (https=)
JP2012504955A5 (https=)
JP2011173884A5 (https=)
HRP20231196T1 (hr) Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba
HRP20170882T1 (hr) Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse
RU2013110874A (ru) Антитела против il-18r1 и их применения
JP2012512641A5 (https=)
JP2012524071A5 (https=)
HRP20191219T1 (hr) Molekule protutijela koje imaju specifičnost za ljudski ox40